Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 4/20 | 0.73 |
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.73 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.59 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.59 |
| ▸ | HRH1 | P35367 | 2/20 | 0.48 |
| ▸ | AKT2 | P31751 | 1/20 | 0.43 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.41 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.39 |
| ▸ | GABBR1 | Q9UBS5 | 1/20 | 0.39 |
| ▸ | AKT1 | P31749 | 1/20 | 0.39 |
| ▸ | PNMT | P11086 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL149259 | 0.85 | HTR2A (1.00) | HTR2ATAAR1CHRNB2CHRNA4HRH1 | |
| Hydrochloric Acid SCHEMBL8550503 | 0.83 | HTR2A (0.94) | HTR2ATAAR1CHRNB2CHRNA4HRH1 | |
| Water SCHEMBL28365853 | 0.83 | HTR2A (0.94) | HTR2ATAAR1CHRNB2CHRNA4HRH1 | |
| Bromide SCHEMBL6737914 | 0.83 | HTR2A (0.94) | HTR2ATAAR1CHRNB2CHRNA4HRH1 | |
| 2,2,2-Trifluoroethanaminium SCHEMBL8355789 | 0.81 | PNMT (0.56) | HTR2ATAAR1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL605443 | 0.81 | HTR2A (0.64) | HTR2ATAAR1CHRNB2CHRNA4SLC6A2 | |
| SCHEMBL38652540 | 0.80 | HTR2A (0.89) | HTR2ATAAR1CHRNB2CHRNA4HRH1 | |
| Hydroxyamine SCHEMBL4363096 | 0.80 | HTR2A (0.89) | HTR2ATAAR1CHRNB2CHRNA4HRH1 | |
| SCHEMBL4743517 | 0.78 | HTR2A (0.59) | HTR2ATAAR1CHRNB2CHRNA4PNMT | |
| SCHEMBL3910286 | 0.77 | HTR2A (0.73) | HTR2ATAAR1CHRNB2CHRNA4HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1877401-A2 | NOVEL COMPOUNDS USEFUL FOR BRADYKININ B1 RECEPTOR ANTAGONISM | Elan Pharmaceuticals Inc. (US) | 2008-01-16 | — | — | EP | claimed |
| US-20070032475-A1 | Novel compounds useful for bradykinin B1 receptor antagonism | ELAN PHARMACEUTICALS, INC. | 2007-02-08 | — | — | US | claimed |
| WO-2006113140-A2 | NOVEL COMPOUNDS USEFUL FOR BRADYKININ B1 RECEPTOR ANTAGONISM | ELAN PHARMACEUTICALS, INC. (US) | 2006-10-26 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032475-A1 | Novel compounds useful for bradykinin B1 receptor antagonism | BDKRB1, BDKRB2, NPBWR1 | HTR2A 742/4885TAAR1 228/4885CHRNB2 309/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.